EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cardiorenal outcomes and mortality after sodium‐glucose cotransporter‐2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history

Jin Hwa Kim iD, Young Sang Lyu, BongSeong Kim, Mee Kyung Kim iD, Sang Yong Kim, Ki-Hyun Baek, Ki-Ho Song, Kyungdo Han iD, Hyuk-Sang Kwon iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Jin Hwa Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Chosun University Hospital, Chosun University School of Medicine, Gwangju, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Percutaneous Coronary Intervention, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Handok Inc, National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the effects of initiating sodium‐glucose cotransporter‐2 (SGLT2) inhibitors on cardiorenal outcomes and mortality compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors as active comparators in patients diagnosed with type 2 diabetes with a history of percutaneous coronary intervention (PCI). Materials and Methods We used an active‐comparator, new‐user design and nationwide data from the National Health Insurance Service in South Korea from 2014 to 2019. Of the 56 392 patients who underwent PCI, 4610 new SGLT2 inhibitor users were paired 1:1 with DPP‐4 inhibitor users for analysis using propensity‐score matching.

Results

During 13 708.59 person‐years of follow‐up, the initiation of SGLT2 inhibitors, compared with the initiation of DPP‐4 inhibitors, was associated with a significantly lower risk of composite repeat revascularization, myocardial infarction, stroke, heart failure (HF), all‐cause death and end‐stage renal disease (ESRD). The beneficial effects of SGLT2 inhibitor use were consistent with the components of stroke, HF, all‐cause death and ESRD. In the cohort that included health examination data, including anthropometric and metabolic factors, new use of SGLT2 inhibitors was associated with a significantly lower risk of HF (hazard ratio [HR] 0.574, 95% confidence interval [CI] 0.36–0.915), all‐cause death (HR 0.731, 95% CI 0.567–0.942), and ESRD (HR 0.076, 95% CI 0.018–0.319). The effects of SGLT2 inhibitor use were consistent regardless of the timing of the previous PCI.

Conclusions

The initiation of SGLT2 inhibitors in patients with type 2 diabetes and a history of PCI was significantly associated with a reduced risk of cardiorenal consequences and mortality, irrespective of time since the last PCI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Percutaneous Coronary InterventionSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedDipeptidyl-Peptidase IV InhibitorsRepublic of KoreaTreatment Outcome

Stichwörter der Autor:innen

SGLT2 inhibitorpercutaneous coronary interventiontype 2 diabetes

Substanzen

Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Chosun University Hospital, Chosun University School of Medicine, Gwangju, Republic of Korea.
  • Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

ORCID-Profile: Jin Hwa Kim, Mee Kyung Kim, Kyungdo Han, Hyuk-Sang Kwon

Förderung

  • Handok Inc
  • National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)

Zitieren

APA

Kim, J. H., Lyu, Y. S., Kim, B., Kim, M. K., Kim, S. Y., Baek, K. H., Song, K. H., Han, K., & Kwon, H. S. (2024). Cardiorenal outcomes and mortality after sodium‐glucose cotransporter‐2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15565

Vancouver

Kim JH, Lyu YS, Kim B, Kim MK, Kim SY, Baek KH, et al. Cardiorenal outcomes and mortality after sodium‐glucose cotransporter‐2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15565

BibTeX
@article{Kim2024,
  author = {Kim, Jin Hwa and Lyu, Young Sang and Kim, BongSeong and Kim, Mee Kyung and Kim, Sang Yong and Baek, Ki-Hyun and Song, Ki-Ho and Han, Kyungdo and Kwon, Hyuk-Sang},
  title = {Cardiorenal outcomes and mortality after sodium‐glucose cotransporter‐2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15565}
}
Kostenlos starten →